JS009 / Shanghai Junshi Bioscience - LARVOL DELTA

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | N=254 ➔ 0 | Not yet recruiting ➔ Withdrawn

Combination therapy • Enrollment change • Metastases • Monotherapy • Trial withdrawal • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies (clinicaltrials.gov) - P1 | N=254 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Combination therapy • Monotherapy • New P1 trial • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors (GlobeNewswire) - "Shanghai Junshi Bioscience...today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its anti-CD112R monoclonal antibody (TAB009/JS009) for the treatment of advanced solid tumors..."

IND • Oncology • Solid Tumor